The estimated Net Worth of James F Polewaczyk is at least $24.9 Миллион dollars as of 6 March 2024. Mr Polewaczyk owns over 8,104 units of Idexx Laboratories stock worth over $9,224,242 and over the last 18 years he sold IDXX stock worth over $14,605,054. In addition, he makes $1,105,636 as Exec. VP & Chief Commercial Officer at Idexx Laboratories.
Mr has made over 16 trades of the Idexx Laboratories stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 8,104 units of IDXX stock worth $3,423,535 on 6 March 2024.
The largest trade he's ever made was selling 22,909 units of Idexx Laboratories stock on 29 August 2023 worth over $11,696,419. On average, Mr trades about 3,719 units every 184 days since 2007. As of 6 March 2024 he still owns at least 18,815 units of Idexx Laboratories stock.
You can see the complete history of Mr Polewaczyk stock trades at the bottom of the page.
James F. Polewaczyk is the Exec. VP & Chief Commercial Officer at Idexx Laboratories.
As the Exec. VP & Chief Commercial Officer of Idexx Laboratories, the total compensation of Mr Polewaczyk at Idexx Laboratories is $1,105,636. There are 11 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Mr Polewaczyk is 56, he's been the Exec. VP & Chief Commercial Officer of Idexx Laboratories since . There are 16 older and 7 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
James's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers и Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: